Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (71-80 of 301) with videos related to

Pageof 31
Sort By:
Clinical Orthopaedics and Related Research|January 24, 2007
Trends in cost effectiveness analyses in orthopaedic surgeryCarmen A Brauer, Peter J Neumann, Allison B Rosen
The American Journal of Managed Care|December 21, 2019
Outcome measures for oncology alternative payment models: practical considerations and recommendationsJakub P Hlávka, Pei-Jung Lin, Peter J Neumann
Health Services Research|June 4, 2021
Value-based drug pricing in the Biden era: Opportunities and prospectsPeter J Neumann, Daniel A Ollendorf, Joshua T Cohen
American Journal of Public Health|October 17, 2008
Measuring the value of public health systems: the disconnect between health economists and public health practitionersPeter J Neumann, Peter D Jacobson, Jennifer A Palmer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 28, 2024
Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness AnalysesFeng Xie, Ting Zhou, Brittany Humphries, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2019
Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care PharmacyLouis P Garrison, Peter J Neumann, Richard J Willke
Pharmacoeconomics|July 8, 2011
US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness researchPeter J Neumann, Pei-Jung Lin, Tom E Hughes
Health Policy (Amsterdam, Netherlands)|December 16, 2014
Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)James D Chambers, Michael J Cangelosi, Peter J Neumann
Journal of Managed Care Pharmacy : JMCP|November 6, 2008
Drug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999Jennifer A Palmer, Alison R Timm, Peter J Neumann
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 19, 2020
Preparing the health-care system to pay for new Alzheimer's drugsPei-Jung Lin, Joshua T Cohen, Peter J Neumann
Pageof 31

Showing results (71-80 of 301) with videos related to

Sort By:
Pageof 31
Clinical Orthopaedics and Related Research|January 24, 2007
Trends in cost effectiveness analyses in orthopaedic surgeryCarmen A Brauer, Peter J Neumann, Allison B Rosen
The American Journal of Managed Care|December 21, 2019
Outcome measures for oncology alternative payment models: practical considerations and recommendationsJakub P Hlávka, Pei-Jung Lin, Peter J Neumann
Health Services Research|June 4, 2021
Value-based drug pricing in the Biden era: Opportunities and prospectsPeter J Neumann, Daniel A Ollendorf, Joshua T Cohen
American Journal of Public Health|October 17, 2008
Measuring the value of public health systems: the disconnect between health economists and public health practitionersPeter J Neumann, Peter D Jacobson, Jennifer A Palmer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 28, 2024
Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness AnalysesFeng Xie, Ting Zhou, Brittany Humphries, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2019
Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care PharmacyLouis P Garrison, Peter J Neumann, Richard J Willke
Pharmacoeconomics|July 8, 2011
US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness researchPeter J Neumann, Pei-Jung Lin, Tom E Hughes
Health Policy (Amsterdam, Netherlands)|December 16, 2014
Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)James D Chambers, Michael J Cangelosi, Peter J Neumann
Journal of Managed Care Pharmacy : JMCP|November 6, 2008
Drug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999Jennifer A Palmer, Alison R Timm, Peter J Neumann
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 19, 2020
Preparing the health-care system to pay for new Alzheimer's drugsPei-Jung Lin, Joshua T Cohen, Peter J Neumann
Pageof 31